Peginterferon Beta-1A

CHEMBL2108677 Phase 4 Approved Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A pegylated form of interferon beta-1a used to reduce the frequency of relapses and slow disability progression in relapsing forms of multiple sclerosis. The pegylation allows for less frequent dosing, requiring injection only every two weeks.

Therapeutic Areas

Multiple Sclerosis Systemic Lupus Erythematosus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A pegylated form of interferon beta-1a used to reduce the frequency of relapses and slow disability progression in relapsing forms of multiple sclerosis. The pegylation allows for less frequent dosing, requiring injection only every two weeks.

Yes, Peginterferon Beta-1A is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108677. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Looking for patient-friendly information?

Peginterferon Beta-1A on PillFYI

Quick Data

Synonyms: 1

External Links

ChEMBL CHEMBL2108677

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.